AI Index / Tempus AI, Inc. Class A Common Stock
Tempus AI, Inc. Class A Common Stock (TEM)
Tempus AI's main sources of revenue include its Genomics business, which involves hereditary and somatic testing, as well as a growing Data and Services segment that includes data licensing. AI contributes directly to these revenue sources, especially in the development of diagnostic tools and data products. The company's recent acquisition of Ambry Genetics enhances its genomic capabilities and aligns with its strategy to integrate AI across diagnostics. Overall, AI is a significant contributor to Tempus' revenue streams.
Loading...
The combination of the two of us on an annualized basis will also be now adjusted EBITDA and cash flow positive. We’re excited that the combination of the two of us on an annualized basis will also be now adjusted EBITDA and cash flow positive.
- Eric Lefkofsky
Similar Companies in the Swift AI Index
Quotes from tempus-ai-inc-class-a-common-stock Executives About Artificial Intelligence and Generative AI
We are really one of the leading companies bringing AI to health care and, in particular, diagnostics.
- Eric Lefkofsky
...what most people don’t understand when they look at our Data businesses, it’s not just that we have lots of data, which we obviously do. But we’ve built a whole series of tools and data products that make that data usable by biotechs and pharmaceutical companies. And that’s really the main differentiation.
- Eric Lefkofsky
...more and more large medical systems are trying to figure out how to take advantage of this new onslaught of generative AI and large language model capabilities.
- Eric Lefkofsky
...you could have millions of people that are benefiting in some way from these things without generating lots of revenue because we still haven’t figured out, at least in the U.S., how to appropriately pay for the benefit of these purely algorithmic diagnostics.
- Eric Lefkofsky